Low expression or promoter hypermethylation of MGMT is correlated with a favorable outcome of glioblastoma patients who received temozolomide, because these cancer cells are unable to efficiently repair temozolomide-induced alkylations [28,29]. This evidence concerns the gene MGMT and glioblastoma.